General Information of Drug (ID: DMMZQVS)

Drug Name
GYKI-16084 Drug Info
Synonyms Uroflux; IDR-16084; (+)-(R)-2-[3-(Benzo-1,4-dioxan-2-ylmethylamino)propyl]pyridazin-3(2H)-one hydrochloride
Indication
Disease Entry ICD 11 Status REF
Prostate disease GA91 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
154069
CAS Number
CAS 185739-21-3
TTD Drug ID
DMMZQVS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [3]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [4]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [5]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [6]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [7]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [8]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [9]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [10]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [11]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [13]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [14]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [15]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [16]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [17]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [18]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [19]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [20]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [21]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Antagonist [2]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010746)
2 A novel approach to the treatment of benign prostatic hyperplasia. BJU Int. 2006 Jun;97(6):1252-5.
3 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
4 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
6 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
7 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
8 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
9 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
10 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
11 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
12 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
13 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
14 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
15 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
16 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
17 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
18 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
19 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
20 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
21 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
22 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.